(Bloomberg) -- Biogen Inc.’s Chief Executive Officer is searching for smaller deals to expand its treatment portfolio as the company prepares for a future that he expects will be highly ...

I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen. Yeah. Well, first, companies in our space are ...

Chris Viehbacher, CEO, noted that Biogen is focused on three core priorities: driving growth from its four recently launched products, reprioritizing the pipeline for high-impact projects ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

and top talent," Biogen CEO Christopher Viehbacher said in a statement. BioMed said construction on the 16-story project will begin this year. It is the first building in the 10-acre Kendall ...

For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...

Biogen CEO sees no burning need for more acquisitions Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Biogen's 2025 forecasts hit by declining sales ... Retail & Consumercategory· October 15, 2024 Walgreens to shut 1,200 stores as CEO Wentworth seeks turnaround Walgreens Boots Alliance said ...